Skip to main content
Premium Trial:

Request an Annual Quote

Quanterix Prices $250M Public Stock Offering

NEW YORK – Quanterix said on Thursday that it has priced a public offering of 3,571,428 shares of its common stock at $70.00 per share. The Billerica, Massachusetts-based firm expects gross proceeds of around $250 million from the offering, which it announced on Wednesday.

The company has granted the underwriters a 30-day option to purchase up to an additional 535,714 shares of common stock at the public offering price less underwriting discounts, commissions, and offering expenses.

Goldman Sachs, SVB Leerink, and Cowen are the joint bookrunning managers for the offering, and Canaccord Genuity is the lead manager.

The offering is expected to close on Feb. 8.

Last month, Quanterix received Emergency Use Authorization from the US Food and Drug Administration for its Simoa SARS-CoV-2 N Protein Antigen Test.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.